Molina R, Barak V, van DA, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer - European Group on Tumor Markers recommendations. Tumour Biol 2005;26:281-93.
Bieglmayer C, Szepesi T, Kopp B, Hoffmann G, Petrik W, Guettuoche K, Grundler S, Gregorits M, Strasser M: CA15.3, MCA, CAM26, CAM29 are members of a polymorphic family of mucin-like glycoproteins. Tumor Biol 1991;12:138-148.
Gion M, Mione R, Leon AE, Lüftner D, Molina R, Possinger K, Robertson JF: CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer 2001;37:355-363.
Ebeling FG, Stieber P, Untch M, Ángel D, Konecny GE, Schmidt UM, Fateh-Moghadam A, Seidel D: Serum CEA and CA 15.3 as prognostic factors in primary breast cancer. Br J C 2002:86:217-222
Duffy MJ, Duggan C, Keane R, Hill ADK, McDermott E, Crown J, O’Higgins N: High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: a study of 600 patients with histologically confirmed breast cancer. Clin Chem 2004;50:559-563.
Uehara M, Kinoshita T, Hojo T, Akashi-Tanaka S, Iwamoto E, Fukutomi T. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cáncer. Int J Clin Oncol 2008;13:447-51.
Molina R, AUge Jm, Farrus B, Zanon G, Pahisa J, Muñoz M, Torne M, Filella X, Escudero JM, Fernandez P, Velasco M. Prospective Evaluation of Carcinoembryonic Antigen (CEA) and Carbohydrate Antigen 15.3 (CA 15.3) in Patients with Primary Locoregional Breast Cancer. Clin Chem 2011;56:1148-57
Molina R, Auge Jm, Escudero JM, Fiella X, Zanon G, Pahisa J, Farrus B, Muñoz M, Velasco M. Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. Tumor Biol 2010;31:171-180
|[x] Molina R, Zanon G, Filella X, Moreno F, Jo J, Daniels M, Latre ML, Jimenez Pahisa J, Velasco M, et al: Use of serial carcinoembryonic antigen and CA15.3 antigen and CA15.3 assays in detecting relapse in breast cancer patients. Breast Cancer Res Treat 1995;36:41-48. |[xi]
Tomlinson IP, Whyman A, Barrett JA, Kremer JK: Tumor marker CA15‑3: possible uses in the routine management of breast cancer. Eur J Cancer 1995;31:899‑902.
Molina R, Jo J, Zanon G, Filella X, Farrus B, Munoz M, Latre ML, Pahisa J, Velasco M, Fernandez P, Estape J, Ballesta AM: Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA15.3. Br J Cancer 1996;74:1126-1131.
Jager W. The early detection of disseminated (metastasized) breast cancer by serial tumour marker measurements. Eur J Cancer Prev 1993;2 Suppl 3:133-9.
Kovner F, Merimsky O, Hareuveni M, Wigler N, Chaitchik S. Treatment of disease-negative but mucin-like carcinoma-associated antigen-positive breast cancer patients with tamoxifen: preliminary results of a prospective controlled randomized trial. Cancer Chemother Pharmacol
Nicolini A, Anselmi L, Michelassi C, Carpi A. Prolonged survival by 'early' salvage treatment of breast cancer patients: a retrospective 6-year study. Br J Cancer 1997;76:1106-11.
Chan DW, Beveridge RA, Muss H, Fritsche HA, Hortobagyi G, Theriault R, Kiang D, Kennedy BJ, Eveleigh M: Use of Truquant BR Radioimmunoassay for early detection of breast cancer recurrence in patients with Stage II and Stage III disease. J Clin Oncol 1997; 15: 2322-2328.
Molina R, Escudero JM, Muñoz M, Auge JM, Filella X. Circulating levels of HER-2/neu oncoprotein in breast cancer. Clin Chem Lab Med 2012;50:5-21
Bast RC, Jr., Ravdin P, Hayes DF, Bates S, Fritsche H, Jr., Jessup JM, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-78.
van Dalen A, Heering KJ, Barak V, Peretz T, Cremaschi A, Geroni P, Gion M, Saracchini S, Molina R, Namer M, Stieber P, Sturgeon C, Leonard RCF, Einarsson R: Treatment response in metastatic breast cancer. A multi-centre study comparing UICC criteria and tumor marker changes. Breast 1996;5:82-88.
Robertson JF, Jaeger W, Syzmendera JJ, y cols. The objective measurement of remission and pogression in metastatic breast cancer by use of serum tumor markers. European Group for Serum Tumor Markers in Breast Cancer. Eur J Cancer 1999;35:47-53.
Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 2006;52:345-51.
Carney WP, The emerging role of monitoring serum HER-2/neu oncoprotein levels in women with metastatic breast cancer. Laboratory Medicine 2003;34:58-64.
Hayes DF, Kiang DT, Korzum AH, Tondini C, Wood WC, Kufe DW. CA15-3 and CEA spikes during chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 1998;7:38.
Yasasever V, Dincer M, Camlica H, Karaloglu D, Dalay N. Utility of CA 15-3 and CEA in monitoring breast cancer patients with bone metastases: special emphasis on "spiking" phenomena. Clin Biochem 1997;30:53-6.
Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligandbinding assay compared with ER, PgR and pS2, by immunohistochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 2000;89:111-7.
Barnes DM, Harris WH, Smith P, Millis RR, Rubens RD. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 1996;74:1445-51.
Pertschuk LP, Feldman JG, Kim YD, Braithwaite L, Schneider F, Braverman AS, Axiotis C. Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Sp gamma in frozen sections or
cytosol-based ligand-binding assays. Cancer 1996;77:2514-9.
Fisher ER, Anderson S, Dean S, Dabbs D, Fisher B, Siderits R, et al. Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma. Cancer 2005;103:164-73.
Bernard-Marty C, Cardoso F, Piccart MJ. Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 2004;9:617-32.
Hammond E et al. American Society of Clinical Oncology-College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J Clin Oncol 2010;28:2784-95.
Wolf et al. American Society of Clinical Oncology-College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J Clin Oncol 2007;25:118-45.
Look MP,van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002;94:116-28.
Janicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, et al. Randomized adjuvant chemotherapy trial in high-risk, lymph nodenegative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst
Duffy MJ. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 2002;48:1194-7.
Sweep CG, Geurts-Moespot J, Grebenschikov N, de Witte JH, Heuvel JJ, Schmitt M, et al. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br J Cancer1998;78:1434-41.
Harbeck N, Kates RE, Look MP, Meijer-van Gelder ME, Klijn JG, Kruger A, et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-typeplasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res 2002;62:4617-22.
Janicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 1994;54:2527-30.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multi-gene assay to predict recurrence of tamoxifen-treated node-negative breast cancer. N Engl J Med 2005;347:2817-26.
Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.J Clin Oncol 2005;23:7265-77.
Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-34.